$HALB Halberd Corp. Signs Significant Revenue Shar
Post# of 630
(Total Views: 93)
Posted On: 01/09/2024 9:15:49 AM
$HALB Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
https://www.accesswire.com/823011/halberd-cor...athena-gtx
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 9, 2024 / Halberd Corporation (OTC PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead , particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division in Germany, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
https://www.accesswire.com/823011/halberd-cor...athena-gtx
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 9, 2024 / Halberd Corporation (OTC PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead , particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division in Germany, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
(0)
(0)Halberd Corporation (HALB) Stock Research Links
Scroll down for more posts ▼